DesignMedix is developing drugs to address the large medical need and markets associated with the rise in drug resistance in multiple diseases. Drug resistance is a huge global and national problem and additional drugs are needed to provide therapeutic options for infectious diseases.

The DesignMedix approach already has led to rapid development of two series of novel drug candidates to overcome resistance in malaria and bacteria, particularly Methicillin Resistant Staphylococcus aureus (MRSA). Several patent-pending anti-malarial drug candidates have shown efficacy in killing drug-resistant malaria parasites cultured in human red blood cells, and have been delivered orally to cure malaria-infected animals - all at very low doses.  The more recent project addressing anti-bacterial agents has had initial success. Using the same technology approach to DesignMedix rapidly designed and made multiple compounds that have broad spectrum activity against many strains of bacteria particularly against drug-resistant MRSA.  The anti-bacterial drug candidates are up to 10 times more effective than drugs commonly used to treat MRSA.